Collagen IV Targeted Perfluorocarbon Nanoparticles for Kidney Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atherosclerosis, hypertension, and kidney diseases, such as lupus nephritis, often result in severe systemic side effects due to non-specific drug administration, highlighting the need for a targeted and minimally invasive delivery system that can effectively address inflammation and injury in blood vessel basement membranes and kidney tissues.
Innovation Solution
Development of novel perfluorocarbon (PFC) nanoparticles conjugated with a collagen IV targeting peptide, which selectively bind to collagen IV in the glomerular basement membrane, allowing for site-specific delivery of pharmaceutically active agents like prednisone, mycophenolate mofetil, or rapamycin, minimizing systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific drug administration is used to treat atherosclerosis, hypertension, and kidney diseases, then the drugs can reach the target tissues, but severe systemic side effects occur
Solution Approach 1:
The invention segments the drug delivery system into targeted nanoparticles that specifically deliver drugs to affected blood vessel basement membranes and kidney tissues, rather than administering drugs systemically. This segmentation allows the drug to be concentrated at the disease site while minimizing exposure to healthy tissues, thereby maintaining treatment efficacy while reducing systemic side effects
Solution Approach 2:
The nanoparticle delivery system implements local quality by concentrating the therapeutic agent specifically at the site of inflammation or injury in the basement membrane or kidney tissue. The targeting ligands on the nanoparticles ensure that the drug is delivered locally to the affected area, creating a high drug concentration where needed while keeping systemic drug levels low, thus resolving the contradiction between effective treatment and systemic toxicity
2Object-affected harmful factors
If targeted nanoparticle delivery system is used, then systemic side effects are minimized, but the complexity of the delivery system increases
Solution Approach 1:
The invention uses nanoparticles as intermediary carriers that simplify the overall treatment approach. Rather than requiring complex surgical interventions or multiple treatment modalities, the nanoparticle mediator delivers the drug directly to the target site through passive or active targeting mechanisms. This intermediary approach reduces systemic side effects while maintaining relatively simple administration procedures, balancing the trade-off between reduced toxicity and system complexity
3Ease of operation
If conventional drug administration is used, then the treatment approach is simple, but the drugs cannot achieve high local concentration at the target site
Solution Approach 1:
The nanoparticle delivery system changes the physical parameters of drug administration by encapsulating the drug in nanoparticles with specific size ranges (typically 10-200 nm). This parameter change allows the drug to remain in circulation long enough to reach the target site, where it can concentrate locally through passive accumulation or active targeting. The nanoparticle formulation maintains ease of intravenous administration while achieving high local drug concentrations that would be impossible with conventional administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted nanoparticle delivery system achieves localized therapeutic effects with reduced side effects, effectively stabilizing atherosclerotic lesions, managing hypertension, and improving kidney function in lupus nephritis by delivering drugs directly to affected areas, thereby enhancing treatment efficacy while minimizing systemic toxicity.
Implementation Method 1
a collagen IV targeting peptide, which selectively bind to collagen IV in the glomerular basement membrane
Data Source
AI summary
A targeting nanoparticle composition and method of treatment for diseases associated with major basement membrane components of blood vessels accessible from blood stream is presented. The composition includes pegylated perfluorocarbon nanoparticles having a targeting ligand attached that targets the basement membrane components, specifically collagen IV. The targeted nanoparticles may contain at least one pharmaceutically active agent capable of treating a glomerular disease such as lupus nephritis.